STOK News

Latest breaking news and updates for STOK stock.

Track all markets on TradingView

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine an...

What impact might the sentiment score of 55 have on market perception and short‑term stock price movement? How does Stoke Therapeutics' valuation multiples (e.g., EV/Revenue, EV/EBITDA) compare to other RNA‑medicine peers? What are the key regulatory risks associated with zorevunersen's development program?
Earnings
12 days ago
Read more businesswire

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential wi...

What is the likely impact on Biogen’s overall pipeline and earnings guidance from the addition of a potential first‑in‑class disease‑modifying therapy for a rare epileptic disorder? How will the partnership with Biogen impact Stoke’s future partnership strategy and potential dilution of existing shareholders? What is the expected pricing and reimbursement outlook for a disease‑modifying therapy for Dravet syndrome, and how might that affect future revenue projections for both companies?
Clinical trials
14 days ago
Read more businesswire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine an...

How does the current valuation (e.g., EV/Revenue, P/E) compare to historical levels and to the broader biotech sector? Are there any upcoming catalysts, such as conference presentations or data readouts, that could move the stock price? Did management address any recent share repurchase activity or dividend policy?
Earnings
18 days ago
Read more businesswire

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine an...

What are the possible short‑term price reactions vs. longer‑term outlook if the presentation contains mixed or ambiguous data? What is the expected timeline for any potential FDA Fast Track, Orphan, or other regulatory designations for zorevunersen? How could the upcoming presentation influence institutional ownership or institutional sentiment toward STOK?
Growth
18 days ago
Read more businesswire